Evidence map›Paper›PMID 34281359›Full record

ArticlePsychiatric services (Washington, D.C.)2022

Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness.

Allison J Ober, Sarah B Hunter, Colleen M McCullough, Isabel Leamon, Michael McCreary, Ivan Beas, Alanna Montero, Derjung M Tarn, Elizabeth Bromley, Brian Hurley and 3 more

Open access · greenAbstract read
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Allison J OberRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Sarah B HunterRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Colleen M McCulloughRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Isabel LeamonRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Michael McCrearyRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Ivan BeasRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Alanna MonteroRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Derjung M TarnRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Elizabeth BromleyRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Brian HurleyRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
John SheeheRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Jeremy MartinezRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Katherine E WatkinsRAND Corporation, Santa Monica, California (Ober, Hunter, McCullough, Leamon, Watkins); David Geffen School of Medicine at University of California, Los Angeles, Los Angeles (McCreary, Beas, Montero, Tarn, Bromley); Los Angeles County Department of Health Services, Los Angeles (Hurley); Los Angeles County Department of Mental Health, Los Angeles (Sheehe, Martinez).
Los Angeles County Department of Mental Health · US

Funding

Implementing Medication-Assisted Therapy for Substance Use Disorders in Mental HealthR34AA025480 · NIAAA · RAND CORPORATION · PI WATKINS, KATHERINE E · 2017 to 2019
$863k
Developing Capacity for Opioid Use Disorder Treatment in Mental HealthR34DA046950 · NIDA · RAND CORPORATION · PI OBER, ALLISON · 2018 to 2020
$801k
NIAAA NIH HHS R34 AA025480NIDA NIH HHS R34 DA046950
6 · The paper itself

Abstract

objectiveThe authors examined the prevalence of co-occurring opioid use disorder and willingness to engage in treatment among clients of eight Los Angeles County Department of Mental Health outpatient clinics.

methodsAdults presenting for an appointment over a 2-week period were invited to complete a voluntary, anonymous health survey. Clients who indicated opioid use in the past year were offered a longer survey assessing probable opioid use disorder. Willingness to take medication and receive treatment also was assessed.

resultsIn total, 3,090 clients completed screening. Among these, 8% had a probable prescription (Rx) opioid use disorder and 2% a probable heroin use disorder. Of the clients with probable Rx opioid use or heroin use disorder, 49% and 25% were female, respectively. Among those with probable Rx opioid use disorder, 43% were Black, 33% were Hispanic, and 12% were White, and among those with probable heroin use disorder, 24% were Black, 22% were Hispanic, and 39% were White. Seventy-eight percent of those with Rx opioid use disorder had never received any treatment, and 82% had never taken a medication for this disorder; 39% of those with heroin use disorder had never received any treatment, and 39% had never received a medication. The strongest predictor of willingness to take a medication was believing that it would help stop opioid use (buprenorphine, β=13.54, p=0.003, and naltrexone long-acting injection, β=15.83, p<0.001).

conclusionsThese findings highlight the need to identify people with opioid use disorder and to educate clients in mental health settings about medications for these disorders.

Indexed as

BuprenorphineOpioid-Related DisordersAdultAnalgesics, OpioidFemaleHeroinHumansMaleMental HealthNaltrexonePrevalenceAnalgesics, OpioidBuprenorphineHeroinNaltrexoneCo-occurring disordersDrug abuseMental health systemsMental illness and opioid use disorderOpioid use disorder medication

Identifiers

PMID34281359
PMCPMC8770719
OpenAlexW3186857976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.